Assenagon Asset Management S.A. Raises Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Assenagon Asset Management S.A. lifted its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 7.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,141,247 shares of the company's stock after acquiring an additional 77,825 shares during the period. Assenagon Asset Management S.A. owned 3.02% of Tarsus Pharmaceuticals worth $37,536,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the stock. Swiss National Bank grew its stake in Tarsus Pharmaceuticals by 1.4% during the 1st quarter. Swiss National Bank now owns 42,433 shares of the company's stock worth $1,542,000 after buying an additional 600 shares during the last quarter. Alpha DNA Investment Management LLC grew its stake in Tarsus Pharmaceuticals by 9.1% during the 2nd quarter. Alpha DNA Investment Management LLC now owns 15,174 shares of the company's stock worth $412,000 after buying an additional 1,261 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Tarsus Pharmaceuticals by 33.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company's stock worth $166,000 after buying an additional 1,530 shares during the last quarter. Profund Advisors LLC grew its stake in Tarsus Pharmaceuticals by 26.8% during the 2nd quarter. Profund Advisors LLC now owns 9,126 shares of the company's stock worth $248,000 after buying an additional 1,929 shares during the last quarter. Finally, Quest Partners LLC purchased a new position in Tarsus Pharmaceuticals during the 2nd quarter worth $61,000. 90.01% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

TARS has been the topic of several research analyst reports. William Blair upgraded Tarsus Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 30th. Oppenheimer reissued an "outperform" rating and issued a $63.00 price objective (up from $61.00) on shares of Tarsus Pharmaceuticals in a report on Friday, August 9th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Tarsus Pharmaceuticals has an average rating of "Buy" and a consensus price target of $51.60.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock traded up $0.52 during mid-day trading on Friday, reaching $39.41. The stock had a trading volume of 657,738 shares, compared to its average volume of 700,626. The business's fifty day moving average is $31.89 and its 200-day moving average is $31.25. The company has a current ratio of 7.03, a quick ratio of 6.99 and a debt-to-equity ratio of 0.28. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -8.95 and a beta of 1.07. Tarsus Pharmaceuticals, Inc. has a 1-year low of $12.87 and a 1-year high of $42.50.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($0.98) by $0.10. The firm had revenue of $40.81 million for the quarter, compared to analyst estimates of $31.30 million. Tarsus Pharmaceuticals had a negative return on equity of 63.99% and a negative net margin of 180.00%. During the same period last year, the company earned ($1.17) earnings per share. On average, research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.7 earnings per share for the current year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.